Reducing bleeding risk in patients on oral anticoagulation therapy

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Oral anticoagulation (OAC) is vital for managing atrial fibrillation (AF) and venous thromboembolism (VTE).
• Major bleeding events are a significant concern, posing life-threatening risks to patients on OAC therapy.
• Bleeding risk is dynamic, influenced by factors beyond static baseline assessments, including age, comorbidities, and drug interactions.

Purpose of the Study:

• To comprehensively review bleeding risks associated with OAC therapy.
• To emphasize the critical balance between assessing thromboembolic and bleeding risks.
• To present clinical tools for estimating stroke and systemic embolism (SSE) and bleeding risk in AF and VTE patients.

Main Methods:

• Literature review of OAC therapy and associated bleeding risks.
• Analysis of clinical tools for risk stratification.
• Discussion of dynamic risk factors and overlapping risk profiles.

Main Results:

• OAC therapy significantly reduces thromboembolic events but necessitates careful bleeding risk management.
• Clinical tools are available to estimate both SSE and bleeding risk in AF and VTE patients.
• Bleeding risk is multifactorial and evolves over time, requiring ongoing assessment.

Conclusions:

• Effective OAC management requires a dynamic assessment of both thromboembolic and bleeding risks.
• Future OAC practices will likely involve personalized approaches and innovative therapies for improved patient safety and outcomes.
• Continuous monitoring and adaptation of OAC strategies are essential for mitigating patient hazards.